You are reading this before you say anything at home, which says something about how you handle hard conversations. Someone you love has been on a weight medication for a while. The dose has gone up more than once, the progress has slowed, and the side effects arrive with each increase. You have heard the same sentence several times, in different words: no program, no coach, no new subscription, only the right medication at a price that makes sense. If the version in your head is "my partner just wants the prescription, so why would anyone pay a membership on top of the drug," this page answers you plainly.
The plain answer comes first: sometimes they should not. A membership like the one GoodLife Health offers is the wrong purchase for a person who wants a prescription and nothing around it, and this page spends as much time on who should walk away as on what the membership does. Below is what your partner would be signing up for, what it costs in full, what it does not do, and a few questions worth asking this week whether or not they ever join. If you want to know first whether they would even qualify, the eligibility check comes before the intake and before any payment.
- If your partner truly wants a prescription and nothing around it, this membership is probably not for them.
- Since the FDA ended the GLP-1 shortages in December 2024 and February 2025, the prescription itself is rarely the scarce part.
- What a membership adds is four cardiometabolic panels a year and a clinician who reads them before deciding.
- GoodLife Health is $299 a month, with $598 at sign-up for the first two months, and medication billed separately by the pharmacy your partner chooses.
- If the clinician cannot accept them, the $598 is refunded in full; once accepted, the first two months are non-refundable.
- The research can be yours, but the intake and the decision are theirs.
What you are weighing, said straight
A common version of this situation goes like this. Your partner started a GLP-1 through an online service, often a compounded version at a low monthly price, because that was what was easy to get. It worked at first. Then the scale stopped moving at a high dose, and what arrived was an email about the next dose up. Nobody drew blood before the increase. Nobody asked whether the nausea or the tiredness meant anything beyond "that is normal on this medication." Then came the news about compounding, and the question in your house moved from whether it was working to whether it was still allowed.
Your partner's position in all of this is reasonable. They are tired of being sold to. They may have watched a low fee turn into a series of add-ons, or a program they never asked for attach itself to a medication they did. What they want sounds simple: the right prescription from someone licensed, filled somewhere they trust, without a sales funnel around it. Raise "a membership" at the wrong moment and it will sound like one more thing being sold to them, and they will have good reason to be wary.
Your position is different. You see the side effects from across the table, you hear the frustration after the scale, and you are the one wondering whether anyone is actually watching. You want to know whether paying a clinician on top of the medication would be care or a more polished upsell. That is the right question. The answer depends on what your partner needs, which we cannot know from here. What we can do is show you what sits underneath the prescription, so the conversation at home is about your partner's health and not about any company, including this one.
What sits underneath "just the prescription"
Two things changed in the last two years, and both bear on the idea of wanting only a prescription. The first is that the scarcity ended. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025, and the last enforcement grace periods for compounding closed in spring 2025. Federal courts declined to block those decisions, and both manufacturers have sued companies selling compounded versions. A narrow exception remains: a pharmacy may still compound for one specific patient with a documented clinical need the branded product cannot meet, such as an allergy to an ingredient. The FDA sets out its concerns about unapproved GLP-1 drugs on its own site.
None of that means your partner did anything wrong. Millions of people used compounded copies legally during the shortage. It does mean that a service still built on mass compounding in 2026 rests on an exception rather than a rule, and that the clinician who signs each of those prescriptions carries the responsibility on their own license. Whether a particular service's use of the exception is appropriate is a legal and clinical question we do not try to answer for you.
The second change is that branded medication now has a price a person can look up. In September 2026, NovoCare listed Wegovy pens at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after that, with the Wegovy pill from $149 a month at lower doses. Through LillyDirect, Zepbound vials were listed at $299 to $449 a month depending on dose. Those are the manufacturers' own published self-pay prices, dated and visible before anyone signs up for anything. Getting the prescription written has become the easy part.
What is left is the part "just the prescription" always skipped: knowing whether it is the right medication, at the right dose, for a reason someone has checked. When a GLP-1 stops working at a high dose, someone should find out why before the dose goes up again. That takes blood work and a clinician who reads it. Fasting glucose, HbA1c, a lipid panel and liver enzymes are standard before a GLP-1 starts, and following markers over time is how anyone sees what the medication is doing.
Getting the prescription written has become the easy part; knowing whether it is still the right one takes blood work and someone who reads it.
A GLP-1 or hormone protocol built without labs is a guess. Clinicians who prescribe without them are cutting a corner that matters.
There is one more thing underneath, and it is the least visible. Our white paper on how GLP-1 telehealth companies make money describes three ways a prescriber gets paid: a margin on the medicine; a low membership fee plus billing insurance; or one flat fee, with the medicine filled at the pharmacy's own price and no share taken. The way a company is paid sets the pressure its clinicians work under and decides what the company is rewarded for, without making anyone good or bad. Where revenue rises with the medicine or the dose, an escalation email is consistent with the incentive, whatever the individual clinician intends. That is worth knowing before your partner decides what "just the prescription" is really costing them.
Taken together, those facts point where the field is going. The shortage is over and the manufacturers publish their prices, so what a prescriber adds in 2026 is the testing and the follow-up around the prescription. If you are comparing services, U.S. News & World Report published its first GLP-1 telehealth ratings in August 2026. GoodLife Health does not appear in them, and we would rather you learn that here than wonder about it.
What the membership does, costs, and leaves out
GoodLife Health is clinician-led precision direct primary care for Cardiometabolic Optimization. The order is fixed: diagnosis first, then treatment, then the long haul. For your partner that would mean blood work before any decision about medication, and blood work every quarter after, read by a clinician who stays.
The $299 a month covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year with every result in your partner's hands, asynchronous messaging with the care team, and video visits. The fee is the same whatever medication is indicated and whatever the dose: no molecule upcharge, no dose upcharge. We call that Medication-Neutral Pricing, and it is the direct answer to the escalation email. A higher dose earns GoodLife Health nothing, so the clinician has no financial reason to reach for one before reading the numbers. Our guide to what a direct primary care membership includes walks through the model in more detail.
When medication is clinically indicated, it is prescribed to the pharmacy your partner chooses, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. What is prescribed is branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic for GLP-1, and any other FDA-approved medication a clinician judges indicated. Compounded GLP-1 is never prescribed here, which means patients pay the branded price, and that price is higher. We chose that knowingly, and it is the first thing your partner should weigh.
Whether insurance covers a branded GLP-1 is between your partner, their plan and the pharmacy, and nobody here can promise it. Prior authorization is the pharmacy's process; GoodLife Health does not claim to run it, speed it or win it. The membership pairs with insurance for catastrophic coverage and does not replace it. What it replaces is the primary-care relationship. The fee is generally eligible for HSA or FSA pre-tax dollars.
The full cost: $598 is charged at sign-up and covers the first two months, then $299 a month, month to month. If the clinician cannot accept your partner into care, the $598 is refunded in full. Once accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. Over a year the membership is $3,588, and the medication is a separate bill at the pharmacy's price. Not everyone is accepted. The path is the eligibility check, the intake, the checkout, then a clinician's review.
What it does not do matters as much as what it does. It does not promise weight loss, a typical result, remission or a cure. It does not promise that a medication will be prescribed at all; the clinician decides, after the labs. It does not cover the hospital, the emergency room or a specialist; insurance stays for those. And it earns nothing on the drug or the dose, which is the point of the model. GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and says so. For a person who wants only a refill, that middle position is money spent on things they will not use. For a person whose medication stopped working and who wants someone to find out why, it is the missing part.
How to raise it at home, or decide not to
The most useful thing you can do this week costs nothing. Before anyone mentions a membership, sit down together and write out four things: the exact medication and dose, and whether the label says it was compounded; the date of the last blood work and who ordered it; the side effects since the last increase; and what the current service said would happen next. If the answer to the second is "never" or "I don't remember," that is the conversation worth having, and it can be had with any clinician your partner trusts, including one they already see.
Raise it as a question rather than a proposal. "When did anyone last check your labs before raising the dose?" invites an answer. "I found a membership" invites a defense. Your partner is the one who would answer the intake, sit for the blood draws and message the clinician. A membership that is your idea and not theirs is $299 a month for a relationship nobody is in.
If their current prescriber already draws labs, reads them with your partner and adjusts on that basis, keep that relationship. That is what we would be offering, and they already have it.
Who this is not for
This section is the reason the page exists, so read it with your partner in mind rather than with hope.
It is not for a person who wants a prescription and nothing else. If your partner wants a refill without labs, without follow-up and without a clinician reading their numbers, the prescription is the smallest part of what they would be paying for, and they would feel every month of it. They would be right to.
It is not for a person who intends to stay on compounded semaglutide or tirzepatide. GoodLife Health prescribes branded medication only. That will not change, and it means a higher pharmacy bill.
It is not for a household where $299 a month plus branded medication at the pharmacy's price would be a strain. We would rather you read that here than discover it after checkout. The manufacturers' published self-pay prices, with a licensed prescriber your partner already has, may be the better next step.
It is not for anyone who needs a guarantee: of weight loss, of a particular drug, of insurance coverage or of a prior authorization approved. We cannot give one, and a page that offered one would deserve your suspicion.
It is not for a person who already has a clinician who tests before treating and stays. Keep that clinician.
And it is not for a partner who has not yet said yes. However carefully you have researched this, the eligibility check, the intake and the decision belong to the person whose health it is. Turning the wrong buyer away before the checkout is deliberate; it protects your partner's money and the clinician's time for the patients who want what the membership does.
If none of that describes your partner, here is the offer without decoration. GoodLife Health is $299 a month, month to month, with $598 charged at sign-up for the first two months; if the clinician cannot accept your partner, the $598 is refunded in full, and once they are accepted the first two months are non-refundable. It buys a cardiometabolic panel every quarter, a clinician who stays, and any indicated medication prescribed to the pharmacy your partner chooses at that pharmacy's price, with nothing taken on it. It returns what a rushed visit never produced: a diagnosis, the markers followed over time, and no repeat of the eight-minute visit. It differs in the one way that matters here: it tests first, treats second and sells neither the drug nor the dose. And the reason to look now is the one you already noticed. The next dose increase is coming, and someone should find out why the medication stopped working before it arrives.
Related Reading
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- What Does a Direct Primary Care Membership Include in 2026
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss